MSD Confirms 2.3bn Doses of Paracox Supplied for Coccidiosis Protection
UK - MSD Animal Health recently celebrated a landmark in poultry vaccine production on making the 500th batch of product with the number of doses manufactured and supplied of Paracox, the leading coccidiosis vaccine, exceeded 2.3 billion.
1 July 2013
3 minute read
Integrated Livestock Business Unit Director David Schofield joined members of production, veterinary, R+D and sales teams from the company at a recent event to mark the occasion. He confirmed the historic and current success of the vaccine: “Since the original development of Paracox with the Institute of Animal Health in the 1980’s the growth in demand for the vaccine has increased substantially every year. Rising from 3million doses a year then to well over 200 million doses a year now.” He continued, “At each stage the manufacturing teams have strived to meet the expectations of our customers and to maintain confidence in its efficacy”
The manufacturing process is one of the most complex in animal health vaccines production as site Director for the UK Animal Health operations Philip Grose explained, “Paracox protects birds against seven strains of Eimeria, the parasites which lead to coccidiosis infection. For the vaccine to be effective and protect against all the strains in one single application a significant degree of specialist skill and management is required in its manufacture.”
David Schofield concluded, “I would like to pay particular tribute to Philip Grose and his team who manage Paracox production. Paracox is recognised worldwide as one of the most successful poultry vaccines ever produced. For over 2.3 billion birds to have been protected from coccidiosis through its manufacture is an incredible achievement.”
